ES2650740T3 - Composición de vacuna con unas nanopartículas de hidróxido de aluminio - Google Patents

Composición de vacuna con unas nanopartículas de hidróxido de aluminio Download PDF

Info

Publication number
ES2650740T3
ES2650740T3 ES12744086.5T ES12744086T ES2650740T3 ES 2650740 T3 ES2650740 T3 ES 2650740T3 ES 12744086 T ES12744086 T ES 12744086T ES 2650740 T3 ES2650740 T3 ES 2650740T3
Authority
ES
Spain
Prior art keywords
nanoparticles
vaccine composition
vaccine
boemite
pseudo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12744086.5T
Other languages
English (en)
Spanish (es)
Inventor
Yannick Mathieu
Bénédicte LEBEAU
Valentin Valtchev
Joël Patarin
Marie GARINOT
Jean Haensler
Elisabeth Sauzeat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Sanofi Vaccines US Inc
Original Assignee
Sanofi Pasteur SA
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur SA, Sanofi Pasteur Inc filed Critical Sanofi Pasteur SA
Application granted granted Critical
Publication of ES2650740T3 publication Critical patent/ES2650740T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ES12744086.5T 2011-07-13 2012-07-12 Composición de vacuna con unas nanopartículas de hidróxido de aluminio Active ES2650740T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1156398A FR2977800B1 (fr) 2011-07-13 2011-07-13 Composition vaccinale avec des nanoparticules d'hydroxyde d'aluminium
FR1156398 2011-07-13
PCT/FR2012/051648 WO2013007956A1 (fr) 2011-07-13 2012-07-12 Composition vaccinale avec des nanoparticules d'hydroxyde d'aluminium

Publications (1)

Publication Number Publication Date
ES2650740T3 true ES2650740T3 (es) 2018-01-22

Family

ID=46639612

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12744086.5T Active ES2650740T3 (es) 2011-07-13 2012-07-12 Composición de vacuna con unas nanopartículas de hidróxido de aluminio

Country Status (9)

Country Link
US (1) US9770505B2 (enExample)
EP (1) EP2731622B1 (enExample)
JP (1) JP6111245B2 (enExample)
CN (1) CN103826658A (enExample)
CA (1) CA2838817A1 (enExample)
ES (1) ES2650740T3 (enExample)
FR (1) FR2977800B1 (enExample)
NO (1) NO2731622T3 (enExample)
WO (1) WO2013007956A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107496915B (zh) * 2015-01-23 2025-02-25 四川大学 一种基于氢氧化铝纳米粒的疫苗载体
CN106177939B (zh) * 2015-06-01 2021-01-19 普莱柯生物工程股份有限公司 一种疫苗用佐剂及其应用
CN106421775B (zh) * 2015-08-12 2020-12-01 普莱柯生物工程股份有限公司 一种疫苗用佐剂及含该佐剂的疫苗组合物和其应用
WO2017053594A1 (en) * 2015-09-23 2017-03-30 The Regents Of The University Of California Compositions and methods of using the same for decontamination of skin
CN107041952B (zh) * 2016-02-05 2020-11-10 中国人民解放军军事医学科学院微生物流行病研究所 表面修饰有氧化铝的疫苗及其制备方法和疫苗组合物
EP3463300A1 (en) * 2016-06-01 2019-04-10 Infectious Disease Research Institute Nanoalum particles containing a sizing agent
CN113666404B (zh) * 2021-09-23 2023-07-28 北京智飞绿竹生物制药有限公司 一种适合规模化生产的高浓度纳米级氢氧化铝佐剂配制方法
CN118846101A (zh) * 2022-02-18 2024-10-29 广州瑞贝斯药业有限公司 一种铝纳米晶复合免疫药物及其制备方法和应用
GB202215072D0 (en) * 2022-10-13 2022-11-30 Glaxosmithkline Biologicals Sa Process for production of aluminium hydroxide particles
CN115944723A (zh) * 2022-12-22 2023-04-11 中国人民解放军陆军军医大学 基于纳米铝盐与纳米乳的复合物在制备疫苗佐剂中的应用及其产品

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK143689C (da) * 1975-03-20 1982-03-15 J Kreuter Fremgangsmaade til fremstilling af en adsorberet vaccine
US4836948A (en) * 1987-12-30 1989-06-06 Lever Brothers Company Viscoelastic gel detergent compositions
DE69332031T2 (de) * 1993-01-08 2002-12-19 Csl Ltd., Parkville Impfstoffpräparate
ES2284287T3 (es) * 1998-10-16 2007-11-01 Glaxosmithkline Biologicals S.A. Sistemas adyuvantes y vacunas.
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
CN101325967A (zh) * 2005-11-04 2008-12-17 诺华疫苗和诊断有限公司 水包油乳液佐剂含量降低的流感疫苗
ES2377884T3 (es) * 2005-11-04 2012-04-02 Novartis Vaccines And Diagnostics S.R.L. Vacunas contra la gripe que incluyen combinaciones de adyuvantes particulados e inmunopotenciadores
JP5650406B2 (ja) * 2007-03-07 2015-01-07 ユーティーアイ リミテッド パートナーシップ 自己免疫状態の予防および治療のための組成物および方法
JP2010534622A (ja) * 2007-07-26 2010-11-11 サノフィ パストゥール リミテッド 抗原−アジュバント組成物および方法
EP2419129A2 (en) * 2009-04-14 2012-02-22 Novartis AG Compositions for immunising against staphylococcus aerus

Also Published As

Publication number Publication date
EP2731622A1 (fr) 2014-05-21
FR2977800A1 (fr) 2013-01-18
FR2977800B1 (fr) 2014-03-14
JP2014520836A (ja) 2014-08-25
WO2013007956A1 (fr) 2013-01-17
JP6111245B2 (ja) 2017-04-05
NO2731622T3 (enExample) 2018-03-10
US20140234422A1 (en) 2014-08-21
US9770505B2 (en) 2017-09-26
EP2731622B1 (fr) 2017-10-11
CA2838817A1 (fr) 2013-01-17
CN103826658A (zh) 2014-05-28

Similar Documents

Publication Publication Date Title
JP6111245B2 (ja) 水酸化アルミニウムナノ粒子を含むワクチン組成物
Firdaus et al. Developments in vaccine adjuvants
CA2621373C (en) Immunogenic complex formed by vaccinal antigens encapsulated by nanostructured mesoporous silica
JP7063957B2 (ja) エンテロウイルス不活化およびアジュバント吸着のための改良された方法、ならびに、それから得られる投与量減量ワクチン組成物
Teng et al. Bio-mineralization of virus-like particles by metal–organic framework nanoparticles enhances the thermostability and immune responses of the vaccines
MX2007016412A (es) Emulsion adyuvante inmunologica.
JP7795235B2 (ja) Ａｌ－Ｍｎ複合ナノ結晶及びその製造方法と使用
DK2833914T3 (en) ADMINISTRATIVE SYSTEM FOR ORAL VACCINE ADMINISTRATION
EP2310045A1 (en) Rapid responses to delayed booster immunisations
Gupta et al. Adjuvants in micro‐to nanoscale: current state and future direction
US9248180B2 (en) IC31 nanoparticles
CA2866426A1 (en) Adjuvanted formulations of rabies virus immunogens
JPWO2017047095A1 (ja) リン酸カルシウムのワクチンアジュバントとしての生理学的特性の最適化
CA2927676A1 (en) Calcium fluoride compositions
Chawla et al. Evaluation of physicochemical properties of aluminium phosphate gel to improve adjuvanticity
CA2927652A1 (en) Calcium fluoride compositions
KR101945265B1 (ko) 백신 조성물을 제조하는 방법
Bansal et al. Evaluation of effectiveness of polymeric nanoparticles based vaccine delivery system over varying time intervals using tetanus toxoid as model antigen
BR112017007089B1 (pt) Método para a produção de uma composição compreendendo partículas enterovirais
TW201908481A (zh) 使腸病毒去活化之改良方法、佐劑吸附及所獲得之劑量減少的疫苗組成物
MXPA00012384A (en) Adjuvant and vaccine compositions containing monophosphoryl lipid a